NCT04563871View on ClinicalTrials.gov

Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

November 17, 2020

Primary Completion Date

October 25, 2023

Study Completion Date

October 25, 2023

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

80mg Osimertinib

One tablet of 80mg Osimertinib for oral administration per day

Trial Locations (6)

Unknown

ChungBuk National University Hospital, Cheonju

National Cancer Center, Goyang

Seoul National University Bundang Hospital, Seongnam

Asan Medical Center, Seoul

Seoul National University Hospital, Seoul

135-710

Samsung Medical Center, Seoul

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Samsung Medical Center

OTHER